TransEnterix (NYSEAMERICAN:TRXC) Trading 6.3% Higher

TransEnterix, Inc. (NYSEAMERICAN:TRXC) shares traded up 6.3% during trading on Friday . The company traded as high as $1.41 and last traded at $1.36. 7,644,768 shares changed hands during trading, an increase of 195% from the average session volume of 2,588,287 shares. The stock had previously closed at $1.28.

A number of analysts have commented on the company. Zacks Investment Research lowered TransEnterix from a “hold” rating to a “sell” rating in a report on Tuesday, May 21st. BTIG Research raised TransEnterix from a “neutral” rating to a “buy” rating and set a $3.00 price objective for the company in a report on Tuesday, May 14th. Finally, Piper Jaffray Companies assumed coverage on TransEnterix in a report on Wednesday, May 22nd. They set a “neutral” rating and a $1.60 price objective for the company. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $3.52.

TransEnterix (NYSEAMERICAN:TRXC) last posted its earnings results on Thursday, May 9th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). The company had revenue of $2.18 million for the quarter, compared to analysts’ expectations of $4.50 million.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in TransEnterix by 9.1% in the fourth quarter. BlackRock Inc. now owns 13,722,308 shares of the medical instruments supplier’s stock valued at $31,014,000 after acquiring an additional 1,146,566 shares during the last quarter. JPMorgan Chase & Co. increased its stake in TransEnterix by 7.2% in the first quarter. JPMorgan Chase & Co. now owns 8,285,135 shares of the medical instruments supplier’s stock valued at $19,719,000 after acquiring an additional 557,305 shares during the last quarter. Northern Trust Corp increased its stake in TransEnterix by 0.6% in the fourth quarter. Northern Trust Corp now owns 1,968,519 shares of the medical instruments supplier’s stock valued at $4,448,000 after acquiring an additional 10,930 shares during the last quarter. Geode Capital Management LLC increased its stake in TransEnterix by 7.5% in the fourth quarter. Geode Capital Management LLC now owns 1,821,799 shares of the medical instruments supplier’s stock valued at $4,117,000 after acquiring an additional 127,598 shares during the last quarter. Finally, Masters Capital Management LLC increased its stake in TransEnterix by 75.0% in the fourth quarter. Masters Capital Management LLC now owns 1,750,000 shares of the medical instruments supplier’s stock valued at $3,955,000 after acquiring an additional 750,000 shares during the last quarter.

About TransEnterix (NYSEAMERICAN:TRXC)

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

See Also: What is a Reverse Stock Split?

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.